Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GYRENASDAQ:IMVTNASDAQ:MRUSNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$6.41-17.0%$11.09$6.17▼$19.00$600.05M1.9387,028 shs404,891 shsIMVTImmunovant$15.20-11.1%$20.23$15.04▼$34.47$2.58B0.681.13 million shs3.71 million shsMRUSMerus$39.60-5.9%$44.03$37.77▼$61.61$2.74B1.15696,664 shs1.76 million shsRYTMRhythm Pharmaceuticals$50.00-5.6%$55.22$35.17▼$68.58$3.16B2.3510,879 shs653,198 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics-15.26%-16.18%-33.45%-36.20%-55.84%IMVTImmunovant-6.97%-12.09%-17.04%-31.01%-47.11%MRUSMerus-5.65%-13.70%-10.62%+0.10%-6.53%RYTMRhythm Pharmaceuticals-3.34%-1.40%-3.53%-5.38%+22.25%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGYREGyre Therapeutics0.1918 of 5 stars0.00.00.00.03.11.70.0IMVTImmunovant2.5412 of 5 stars4.50.00.00.02.82.50.0MRUSMerus2.3428 of 5 stars4.60.00.00.02.81.70.0RYTMRhythm Pharmaceuticals4.4167 of 5 stars4.53.00.04.32.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre Therapeutics 3.00BuyN/AN/AIMVTImmunovant 3.00Buy$41.00169.74% UpsideMRUSMerus 3.13Buy$85.31115.42% UpsideRYTMRhythm Pharmaceuticals 2.92Moderate Buy$69.4638.92% UpsideCurrent Analyst Ratings BreakdownLatest GYRE, RYTM, MRUS, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/24/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/20/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/20/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.003/19/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.003/18/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/18/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$64.00 ➝ $66.003/11/2025GYREGyre TherapeuticsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/10/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/10/2025MRUSMerusBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.003/7/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$72.00 ➝ $72.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$105.76M5.67$0.13 per share50.49$0.18 per share35.61IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AMRUSMerus$36.13M75.72N/AN/A$6.17 per share6.42RYTMRhythm Pharmaceuticals$130.13M24.29N/AN/A$2.87 per share17.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics-$92.93M$0.05128.20∞N/A-84.57%-118.43%-71.97%5/8/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)MRUSMerus-$154.94M-$3.27N/AN/AN/A-680.61%-38.89%-31.16%5/6/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$4.35N/AN/AN/A-230.07%-367.36%-77.47%5/6/2025 (Estimated)Latest GYRE, RYTM, MRUS, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 million2/27/2025Q4 2024MRUSMerus-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 million2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 million2/10/2025Q3 2025IMVTImmunovant-$0.68-$0.76-$0.08-$0.76N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A3.723.29IMVTImmunovantN/A6.046.04MRUSMerusN/A8.328.32RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%IMVTImmunovant47.08%MRUSMerus96.14%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics19.52%IMVTImmunovant5.90%MRUSMerus4.57%RYTMRhythm Pharmaceuticals5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics4093.61 million75.27 millionNo DataIMVTImmunovant120169.86 million159.84 millionOptionableMRUSMerus3769.09 million65.34 millionOptionableRYTMRhythm Pharmaceuticals14063.22 million58.02 millionOptionableGYRE, RYTM, MRUS, and IMVT HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 30 at 4:20 AM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 2.4% - What's Next?March 29 at 5:07 PM | marketbeat.comLoomis Sayles & Co. L P Sells 18,143 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)March 29 at 5:47 AM | marketbeat.comHC Wainwright Issues Negative Forecast for RYTM EarningsMarch 28, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Rhythm Pharmaceuticals (RYTM)March 27, 2025 | markets.businessinsider.comQ1 EPS Forecast for Rhythm Pharmaceuticals Cut by AnalystMarch 27, 2025 | marketbeat.comQ2 Earnings Forecast for RYTM Issued By HC WainwrightMarch 27, 2025 | americanbankingnews.comQ2 Earnings Estimate for RYTM Issued By HC WainwrightMarch 26, 2025 | marketbeat.comCibc World Markets Corp Purchases New Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)March 26, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 344 Shares of StockMarch 25, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Receives "Buy" Rating from HC WainwrightMarch 25, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given "Buy" Rating at HC WainwrightMarch 25, 2025 | americanbankingnews.com7RYTM : Analyst Expectations For Rhythm Pharmaceuticals&#...March 24, 2025 | benzinga.comConnor Clark & Lunn Investment Management Ltd. Buys New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)March 24, 2025 | marketbeat.comRhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in JapanMarch 21, 2025 | pharmabiz.comRhythm Pharmaceuticals receives orphan drug status in JapanMarch 21, 2025 | investing.comRhythm Pharmaceuticals reacquires rights to Imcivree in China for $6.3MMarch 21, 2025 | markets.businessinsider.comIs Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?March 21, 2025 | msn.comRhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.March 20, 2025 | globenewswire.comRhythm Pharmaceuticals gets orphan drug designation for setmelanotide in JapanMarch 20, 2025 | markets.businessinsider.comYann Mazabraud Sells 75,000 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockMarch 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGYRE, RYTM, MRUS, and IMVT Company DescriptionsGyre Therapeutics NASDAQ:GYRE$6.41 -1.31 (-16.97%) Closing price 04:00 PM EasternExtended Trading$6.43 +0.02 (+0.33%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Immunovant NASDAQ:IMVT$15.20 -1.89 (-11.06%) Closing price 04:00 PM EasternExtended Trading$15.08 -0.12 (-0.79%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Merus NASDAQ:MRUS$39.60 -2.49 (-5.92%) Closing price 04:00 PM EasternExtended Trading$39.62 +0.02 (+0.04%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Rhythm Pharmaceuticals NASDAQ:RYTM$50.00 -2.97 (-5.61%) Closing price 04:00 PM EasternExtended Trading$50.02 +0.02 (+0.04%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
